Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Continued reduction in cancer incidence associated with longer raloxifene use
December 23rd, 2004
Raloxifene (Evista; Eli Lilly and Co.) continues to be associated with more than a 50% reduction in breast cancer incidence beyond the first 4 years of treatment, study results show. The randomized, double-blind Multiple Outcomes of Raloxifene Evaluation (MORE) trial found that, in postmenopausal women with osteoporosis, 4 years of treatment with raloxifene was associated with a 72% reduction in breast cancer incidence compared with placebo. The Continuing Outcomes Relevant to Evista (CORE) trial was designed to examine the effect of an additional 4 years of treatment with raloxifene in the same group of women. The findings were published in the...
Source: Women's Health Weekly (2004-12-23)
|
